ISBN: 9781455750658 - drug safety: managing innovation in rheumatology, an issue of rheumatic disease clinics: volume 38-4 (2 risultati)

Perfeziona la tua ricerca

  • Libri (2)

  • Nuovo (2)

  • Con foto (2)

a

Fascia di prezzo personalizzata (EUR)

a

  • Lingua: Inglese

    Editore: Elsevier Health Sciences Nov 2012, 2012

    1455750654 / 9781455750658

    • Rilegato
    • Print on Demand

    Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 81,99

    EUR 23,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 2 disponibili

    Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today--drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities. 240 pp. Englisch.…

  • Lingua: Inglese

    Editore: Elsevier Health Sciences, 2012

    1455750654 / 9781455750658

    • Rilegato
    • Print on Demand

    Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 102,19

    EUR 35,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 2 disponibili

    Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today--drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.…